SAC Capital Advisors’s Pacira BioSciences PCRX Stock Holding History

SAC Capital Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-82,506	Closed	-$5.78M	–	745
2014 Q1	$5.78M	Sell	82,506 -21,094	-20%	-$1.43M	0.03%	537
2013 Q4	$5.96M	Buy	103,600 +18,300	+21%	+$962K	0.03%	465
2013 Q3	$4.1M	Sell	85,300 -25,400	-23%	-$926K	0.02%	569
2013 Q2	$3.21M	Buy	+110,700	New	+$3.2M	0.02%	624

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

SAC Capital Advisors's PCRX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Pacira BioSciences (PCRX) in Q2 2014, closing a stake of 82,506 shares — an estimated $5.78M sold.

SAC Capital Advisors first reported a position in PCRX in Q2 2013 and held it in 4 quarters. The position peaked at $5.96M in Q4 2013. 191 funds tracked by Wall St. Rank hold PCRX as of Q2 2014.

SAC Capital Advisors reported no remaining Pacira BioSciences position as of Q2 2014 after selling out during the quarter.
SAC Capital Advisors sold 82,506 Pacira BioSciences shares in Q2 2014, an estimated $5.78M.
SAC Capital Advisors first reported a position in Pacira BioSciences in Q2 2013 and held it in 4 quarters.
SAC Capital Advisors's Pacira BioSciences position peaked at $5.96M in Q4 2013.
191 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.